Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Chronic or non-healing lower extremity ulcerations in diabetics are a significant cause of morbidity and mortality, and account for a large proportion of the financial burden related to the care of diabetics. Lower extremity ulcerations develop primarily as a consequence of neuropathy and the goal in addressing any wound is to re-establish tissue integrity as soon as possible. The healing of wounds is a complex procedure involving multiple growth factors, some of which have multiple effects on different cell types, in particular, platelet derived growth factor (PDGF) is a prominent agent, active in all stages of the healing process. Becaplermin (0.01% Regranex gel) is a homodimeric protein produced by recombinant DNA technology through the insertion of the gene for the B chain PDGF into the yeast Saccharomyces cerevisiae. The biological activity of becaplermin is similar to that of indigenous PDGF-BB, specifically, the promotion of chemotactic recruitment and the proliferation of cells involved in wound repair. Becaplermin has undergone extensive animal and human studies, demonstrating that it is highly effective as an adjunctive measure for the healing of ulcerations in the feet of diabetics when used in conjunction with standard wound healing practices. Specifically these practices include the provision of a moist environment free of debris and necrotic tissue, control of infection and optimal weight displacement from the affected area. Becaplermin is safe and easy to use, being applied once-daily and at present, becaplermin is the only growth factor licensed for use in wound healing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · cited 1×
“Diabetics face lifelong intensive medical therapy to maintain optimal metabolic homeostasis in the hope of reducing the risk of developing long-term complications associated with this disease [7-9].”
BackgroundSinger, A. J., & Clark, R. A. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411006 · Cited by 6,106
Robson, M. C. (1997) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70572-7 · Cited by 643
Smiell, J. M., Wieman, T. J., Steed, D. L., Perry, B. H., Sampson, A. R., & Schwab, B. H. (1999) · Wound Repair and Regeneration · doi:10.1046/j.1524-475x.1999.00335.x · Cited by 454
Cited by
Regulation of Wound Healing by Growth Factors and Cytokines
WERNER, S., & GROSE, R. (2003) · Physiological Reviews · doi:10.1152/physrev.2003.83.3.835 · Cited by 3,629
Diagnosis and Treatment of Diabetic Foot Infections
Lipsky, B. A., Berendt, A. R., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., LeFrock, J. L., Lew, D. P., Mader, J. T., Norden, C., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424846 · Cited by 1,146
Self-citationDiabetic Wound-Healing Science
Burgess, J. L., Wyant, W. A., Abdo Abujamra, B., Kirsner, R. S., & Jozic, I. (2021) · Medicina · doi:10.3390/medicina57101072 · Cited by 928
Toward delivery of multiple growth factors in tissue engineering
Chen, F.-M., Zhang, M., & Wu, Z.-F. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.053 · Cited by 649
Nanotechnology-Driven Therapeutic Interventions in Wound Healing: Potential Uses and Applications
Hamdan, S., Pastar, I., Drakulich, S., Dikici, E., Tomic-Canic, M., Deo, S., & Daunert, S. (2017) · ACS Central Science · doi:10.1021/acscentsci.6b00371 · Cited by 525
Metadata
- Authors
- Embil, J. M., & Nagai, M. K.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2002-02
- Volume
- 2
- Issue
- 2
- Pages
- 211-218
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1983435477
- Cited by
- 135
- References
- 4
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. https://app.cochat.ai/papers/10.1517/14712598.2.2.211
- The paper
- Embil, J. M., & Nagai, M. K. (2002). Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2.2.211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.